C-VUVEOxitope Pharma
S100A4, OxPL, monoclonal antibodies
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-VUVE
C-VUVEC-VUVES100A4, OxPL, monoclonal antibodies
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The goal of this clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis. Researchers will compare CAL101 with placebo to compare change from baseline in forced vital capacity (FVC). Participants will be randomly assigned to a study group that will receive an IV infusion of either the study medication or placebo about once a month for 6 months.
The first-in-human study will be performed in healthy volunteers and patients with a chronic inflammatory skin disease. The primary objective is to evaluate the safety, tolerability and pharmacokinetics of increasing doses of AX-202 infusion.
What is Sales and Marketing Strategy of Calluna Pharma Company? – businessmodelcanvastemplate.com Skip to content Framework Templates Blogs Search Cart 0 / $0.00 What Are Calluna Pharma's Sales and Marketing Strategies? July 11, 2025 CALLUNA PHARMA BUNDLE Get the Full Package: 5 Forces $15 $10 BCG Matrix $15 $10 Canvas $15 $10 Marketing Mix $15 $10 PESTLE $15 $10 SWOT Analysis $15 $10 TOTAL: ADD TO CART How Is Calluna Pharma Revolutionizing Biopharmaceutical Sales? The 2024 merger that birthed Calluna Pharma wasn't just a corporate reshuffle; it was a strategic leap, uniting expertise to
Calluna Pharma | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Calluna Pharma Website: Calluna Pharma Business Area(s) Immunotherapy Inflammation Description Calluna Pharma's approach is to target upstream innate immune amplifiers that underpin persistent inflammatory and fibrotic responses to restore tissue homeostasis and disrupt disease progression.
What is Sales and Marketing Strategy of Calluna Pharma Company? – businessmodelcanvastemplate.com Skip to content Framework Templates Blogs Search Cart 0 / $0.00 What Are Calluna Pharma's Sales and Marketing Strategies? July 11, 2025 CALLUNA PHARMA BUNDLE Get the Full Package: 5 Forces $15 $10 BCG Matrix $15 $10 Canvas $15 $10 Marketing Mix $15 $10 PESTLE $15 $10 SWOT Analysis $15 $10 TOTAL: ADD TO CART How Is Calluna Pharma Revolutionizing Biopharmaceutical Sales? The 2024 merger that birthed Calluna Pharma wasn't just a corporate reshuffle; it was a strategic leap, uniting expertise to
Careers - Calluna Pharma Our science Our pipeline Aurora IPF Phase 2 Study Expanded Access Policy About us News Publications Contact Careers We are always looking for enthusiastic and dedicated individuals to join our growing team. Please contact us via this link Open positions At the moment we don’t have any open positions, but follow us on LinkedIn – open positions will be posted both here and on LinkedIn. Why work with us? We believe in the power of immunology to push boundaries, challenge the status quo , and develop therapeutics that will make a real difference for people
Privacy Policy - Calluna Pharma Our science Our pipeline Aurora IPF Phase 2 Study Expanded Access Policy About us News Publications Contact Privacy Policy Calluna Pharma recognizes the importance of processing data about you as an individual, such as your name, address or e-mail address (“Personal Data”). This Privacy Policy sets out how Calluna Pharma (THE COMPANY), with registration number 932 255 189 collects, uses, maintains, processes and discloses personal identification information (Personal Data) collected from users (each, a “User”) of the www.callunapharma.com website (&# … ersonal Data. We will collect Personal Data from Users only if they voluntarily submit such information to us. Users can always refuse to supply Personal Data, but it may prevent them from engaging in certain Site related activities. If you have any questions about this privacy policy or our privacy practices, please contact our data privacy manager in the following ways: Full name of legal entity: Calluna Pharma Email address: [email protected] Postal address: Ga … swer your questions. For recruiting purposes, we may collect and store your CV, application, certificates and references. Use of this Personal Data is based on your consent. To personalise user experience, we may use Personal Data in the aggregate to understand how our Users as a group use the services and resources provided on our Site. To improve our Site we may use feedback provided through analytic tools to improve our products and services. This site uses the Google Anal
Exclusive: Calluna emerges from the merger of biotechs Oxitope Pharma and Arxx Therapeutics, closes €75M Series A raise | Oystein Soug LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Cont
Newly launched Calluna raises $81m to advance monoclonal antibody pipeline - Pharmaceutical Technology Skip to site menu Skip to page content Switch language: .translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Pharma Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Ins
Calluna Pharma AS Asset Profile | Preqin Skip to main content Products Our products Preqin Pro Alternative assets data platform Private Markets Research Industry research Term Intelligence Benchmark LPA terms Preqin Benchmarks Industry's leading performance data Preqin Sustainability ESG data and insights Company Intelligence Companies & deals data Enterprise Data Solutions Flexible data delivery solutions Transaction Intelligence A $5.4tn transaction repository Client stories What our clients say Quick Links Our data Asset classes we cover Create a free account Newsletter Contribute … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Quick Links Our data Asset classes we cover Create a free account Newsletter Contribute data Contact us Insights+ Private markets research Homepage Browse reports Search Search the research library Webinar recordings Join conversations with our analysts Meet the analysts Meet the team behind the reports Learn more Learn more about Private Markets Resear … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Insights+ Homepage Search Webinar recordings Meet the analysts Learn more News & content Homepage Events Free Benchmarks Data coverage map Preqin Profiles Preqin Academy Compensation calculator About Who we are Our corporate responsibility Partners Press hub Careers Contact us QuickLinks Our data Asset classes we cover Create a free account Newslett … ed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers. Request demo Calluna Pharma AS - overview Established 2024 Location Oslo, -, Norway Primary Industry Biotechnology About Based in Oslo, Norway, and founded in 2024, Calluna Pharma AS, formed from the merger of Oxitope Pharma and Arxx Therapeutics, operates as a clinical-stage biotechnology company. In January 2024, the … go Pro Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more. Sign in Request demo Our Company Who We Are Our Corporate Responsibility Partners
Calluna Pharma Jobs in Nordic Life Science Startups - Life Science Talent Hub Jobs Companies Podcast Tips & Resources Pricing & Services Contact Login Post a Job Jobs Companies Podcast Tips & Resources Pricing & Services Contact Login Post a Job Info Close Employers search Careers at Calluna Pharma 1 job no.linkedin.com New Jobs Administrative Coordinator Full-time • Oslo, NO • 1w ago 1w ago Apply RSS • Jobs • Contact Us © 2026 Life Science Talent Hub
Calluna Pharma Launches and Announces EUR 75 Million Series A Financing to Develop Novel Therapies for Inflammatory and Fibrotic Diseases | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
CAL101 (Calluna Pharma) Calluna Pharma AS - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures to Launch Saturnus Bio Coulter Partners Places Vincent Metzler as CEO of Cellcolabs Europe Unveils … Graph Therapeutics Raises $5m Investment Led by Daphni Kos Technology Partners: Fund Reaches $123m with 3rd Closing Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires BIO 2026 San Diego … ndon 2026 Advanced Therapies Europe 2026 Barcelona » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
Calluna Announces Three Poster Presentations at the 2025 American Thoracic Society International Conference - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends C … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Calluna Announces Three Poster Presentations at the 2025 American Thoracic Society International Conference April 29, 2025 | 2 min read Twitter LinkedIn Facebook Email Print OSLO, Norway & BOSTON--(BUSINESS WIRE)--Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in- … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Calluna Pharma Successfully Completes Phase 1 Clinical Study of CAL101, a First-in-Class Therapeutic for Fibrotic and Fibro-Inflammatory Indications - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Calluna Pharma Successfully Completes Phase 1 Clinical Study of CAL101, a First-in-Class Therapeutic for Fibrotic and Fibro-Inflammatory Indications October 23, 2024 | 2 min read Twitter LinkedIn Facebook Email Print CAL101 is an anti-S100A4 monoclonal antibody (mAb) and Calluna’s lead drug candidate Stud … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Calluna Pharma Announces Initiation of Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Calluna Pharma Announces Initiation of Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis August 26, 2025 | 3 min read Twitter LinkedIn Facebook Email Print CAL101 is a first-in-class monoclonal antibody targeting S100A4, a damage-associated molecular pattern (DAMP) protein associated with s … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Calluna Pharma Announces the Appointment of Gijs van den Brink, MD, PhD, as Independent Director - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gen … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Calluna Pharma Announces the Appointment of Gijs van den Brink, MD, PhD, as Independent Director December 16, 2025 | 2 min read Twitter LinkedIn Facebook Email Print OSLO, Norway & BOSTON--(BUSINESS WIRE)--Calluna Pharma AS, a clinical stage biotechnology company pioneering first-in-class antibodies t … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Calluna Pharma Completes Enrollment in Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis (IPF) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Calluna Pharma Completes Enrollment in Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis (IPF) April 22, 2026 | 3 min read Twitter LinkedIn Facebook Email Print Study of CAL101, which targets a novel upstream pathway implicated in fibrotic disease, enrolls 161 patients more than six months … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Calluna Pharma appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the Board - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Calluna Pharma appoints Mark Gaffney as Chief Executive Officer and Mark Altmeyer as Independent Chair of the Board October 9, 2024 | 3 min read Twitter LinkedIn Facebook Email Print Executive appointments will drive growth strategy and progression of clinical pipeline OSLO, Norway & BOSTON--(BUSINESS … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Publications - Calluna Pharma Our science Our pipeline Aurora IPF Phase 2 Study Expanded Access Policy About us News Publications Contact Publications Posters & Presentations CAL101 2026 April – EU-PFF Summit poster: AURORA – A Global Phase 2 Study of CAL101 2026 February – Keystone Fibrosis poster: Anti‑Inflammatory Potential of CAL101 via S100A4 Neutralization 2025 November – PFF Summit poster: AURORA – A Global Phase 2 Study of CAL101 2025 November – PFF Summit poster: Evaluating the Safety, Tolerability and Pharmacokinetics of CAL101 2025 May – ATS p
Calluna Pharma | Reimagining immunology Our science Our pipeline Aurora IPF Phase 2 Study Expanded Access Policy About us News Publications Contact Harnessing innate power: Targeting the root causes of inflammation and fibrosis By redefining how we target inflammation and fibrosis, Calluna Pharma is paving the way for groundbreaking therapeutics that will change the lives of patients worldwide. Get in touch Our mission Calluna is a global fibrosis and inflammation-focused biotech company driven by a lean, committed team, with first-in-class clinical-stage antibodies in indications of high unme
Calluna Pharma | Reimagining immunology Our science Our pipeline Aurora IPF Phase 2 Study Expanded Access Policy About us News Publications Contact Harnessing innate power: Targeting the root causes of inflammation and fibrosis By redefining how we target inflammation and fibrosis, Calluna Pharma is paving the way for groundbreaking therapeutics that will change the lives of patients worldwide. Get in touch Our mission Calluna is a global fibrosis and inflammation-focused biotech company driven by a lean, committed team, with first-in-class clinical-stage antibodies in indications of high unme
Calluna Pharma | Reimagining immunology Our science Our pipeline Aurora IPF Phase 2 Study Expanded Access Policy About us News Publications Contact Harnessing innate power: Targeting the root causes of inflammation and fibrosis By redefining how we target inflammation and fibrosis, Calluna Pharma is paving the way for groundbreaking therapeutics that will change the lives of patients worldwide. Get in touch Our mission Calluna is a global fibrosis and inflammation-focused biotech company driven by a lean, committed team, with first-in-class clinical-stage antibodies in indications of high unme
Calluna Pharma | Reimagining immunology Our science Our pipeline Aurora IPF Phase 2 Study Expanded Access Policy About us News Publications Contact Harnessing innate power: Targeting the root causes of inflammation and fibrosis By redefining how we target inflammation and fibrosis, Calluna Pharma is paving the way for groundbreaking therapeutics that will change the lives of patients worldwide. Get in touch Our mission Calluna is a global fibrosis and inflammation-focused biotech company driven by a lean, committed team, with first-in-class clinical-stage antibodies in indications of high unme
Calluna Pharma | Reimagining immunology Our science Our pipeline Aurora IPF Phase 2 Study Expanded Access Policy About us News Publications Contact Harnessing innate power: Targeting the root causes of inflammation and fibrosis By redefining how we target inflammation and fibrosis, Calluna Pharma is paving the way for groundbreaking therapeutics that will change the lives of patients worldwide. Get in touch Our mission Calluna is a global fibrosis and inflammation-focused biotech company driven by a lean, committed team, with first-in-class clinical-stage antibodies in indications of high unme
Calluna Pharma | Reimagining immunology Our science Our pipeline Aurora IPF Phase 2 Study Expanded Access Policy About us News Publications Contact Harnessing innate power: Targeting the root causes of inflammation and fibrosis By redefining how we target inflammation and fibrosis, Calluna Pharma is paving the way for groundbreaking therapeutics that will change the lives of patients worldwide. Get in touch Our mission Calluna is a global fibrosis and inflammation-focused biotech company driven by a lean, committed team, with first-in-class clinical-stage antibodies in indications of high unme
Calluna Pharma | Reimagining immunology Our science Our pipeline Aurora IPF Phase 2 Study Expanded Access Policy About us News Publications Contact Harnessing innate power: Targeting the root causes of inflammation and fibrosis By redefining how we target inflammation and fibrosis, Calluna Pharma is paving the way for groundbreaking therapeutics that will change the lives of patients worldwide. Get in touch Our mission Calluna is a global fibrosis and inflammation-focused biotech company driven by a lean, committed team, with first-in-class clinical-stage antibodies in indications of high unme
Calluna Pharma Launches and Announces EUR 75 Million Series A Financing to Develop Novel Therapies for Inflammatory and Fibrotic Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Calluna Pharma Launches and Announces EUR 75 Million Series A Financing to Develop Novel Therapies for Inflammatory and Fibrotic Diseases January 23, 2024 | 4 min read Twitter LinkedIn Facebook Email Print Oxitope Pharma and Arxx Therapeutics, companies with a shared goal of leveraging the innate immune system to discov … herapeutics to create Calluna Pharma is a prime example of our Forbion Ventures Fund’s strategy where we both build new and enable existing companies. As a result, we recognized the strength of combining these two companies’ pioneering approaches to disrupt the treatment of inflammatory and fibrotic diseases, the complementarity of management skills, and the resulting robust clinical pipeline. We look forward to continuing our support of potentially life changing clinical ass … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Calluna Pharma Completes Enrollment in Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis (IPF) - Calluna Pharma Our science Our pipeline Aurora IPF Phase 2 Study Expanded Access Policy About us News Publications Contact Calluna Pharma Completes Enrollment in Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis (IPF) Posted by: Benjamin Dyhre | April 22, 2026 | Press Releases Study of CAL101, which targets a novel upstream pathway implicated in fibrotic disease, enrolls 161 patients more than six months ahead of plan; topline data expected Q1 2027  
Calluna Pharma (Group) - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures to Launch Saturnus Bio Coulter Partners Places Vincent Metzler as CEO of Cellcolabs Europe Unveils a Record 35 New Nvi … Graph Therapeutics Raises $5m Investment Led by Daphni Kos Technology Partners: Fund Reaches $123m with 3rd Closing Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires BIO 2026 San Diego … ndon 2026 Advanced Therapies Europe 2026 Barcelona » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
Calluna Pharma - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Microbiome Drug Discovery Cell Science Ab
Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance | Cambridge Network Skip to main content The Network Membership Who we are Make the most of our services Cambridge Cluster Cambridge NeuroWorks FAQ Companies Member directory News News listing Blog Events All events Cambridge Network events Advertise your event Boost your event Sponsorship Learning Training courses In-house courses Coaching services Graduate scheme Consultancy services Peer groups Learning FAQ Jobs Jobs listing Recruitment Packages Advertise your vacancies Connect w
Delighted to announce the launch of Calluna Pharma - a new clinical stage company developing novel therapies that harness the transformative potential of the body's immune system - formed from our… | Arxx Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choi
Calluna Launches with €75M for Inflammatory, Fibrotic Therapies | Respiratory Therapy Disorders & Diseases Chronic Pulmonary Disorders Infectious Diseases Critical Care Cardiopulmonary & Thoracic Sleep Medicine Public Health Smoking Healthcare & Policy Pediatrics Treatment Products Monitoring & Treatment Diagnostics & Testing Pharmaceuticals Industry & Regulatory News Department Management Clinical Education Conferences & CEU Resources Videos Webinars White Papers Edition Archive Select Page --> Calluna Pharma Launches with €75M for Inflammatory and Fibrotic Disease
S-1/A 1 ck0001540171-20260429.htm S-1/A S-1/A Table of Contents   As filed with the Securities and Exchange Commission on April 29, 2026. Registration No. 333-294932     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933     Avalyn Pharma Inc. (Exact name of registrant as specified in its charter)     Delaware 2834 45-2463191 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number … hat we plan to seek approval for our drug product and the device under a single application. We have chosen nebulized delivery for our current programs, as we believe it offers the best solution for patients with pulmonary fibrosis, who often suffer from chronic cough and compromised lung function. Nebulized formulation produces a soft, gentle mist that allows for normal tidal breathing without requiring forceful inhalation. This minimizes cough induction and improves usabili … r risks. Where approval of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval. • If we experience delays or difficulties in the enrollment and/or retention of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected, and our receipt of necessary regulatory approvals could be delayed or prevented. • The results of clinical tria … adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, while we are an emerging growth company we may not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result of this election, our financial statements may not be comparable to those of ot … together with our existing cash, cash equivalents, and marketable securities to fund the continued development of AP01 and AP02, our two clinical stage programs, and AP03, our preclinical stage program, as well as to fund research and development activities for additional programs, and the remainder for working capital and general corporate purpo
ShareLab member Arxx Therapeutics today announced the merger with Oxitope Pharma. The merged company, named Calluna Pharma, raises EUR 75 million (NOK 860m) in a series A led by Forbion. What a great… | Esben A. Nilssen | 22 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can upda
January 2026 clinical trial highlights | Pulmonary Fibrosis Foundation Skip to Main Content PFF Help Center (844) 825-5733 Facebook LinkedIn YouTube Instagram Join the PFF Registry Donate Shop PFF Menu To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation. Understanding PF Newly Diagnosed: Start Here PF Basics: Info for Newly Diagnosed Patients About Pulmonary Fibrosis What is Pulmonary Fibrosis? Causes Diagnosis Symptoms Glossary and Abbreviations Ty … Scholars and Other Research Opportunities Familial Pulmonary Fibrosis Research Award PROLIFIC Community Engagement Care Center Network Nurse and Allied Health Network Host an Event Book a PFF Ambassador Request Sponsorship Support Ways to Give Ways to Give Workplace & Matching Giving Planned Giving Donor Advised Funds Donate Stocks & Bonds Qualified Charitable Distribution (QCD) Donate Cryptocurrency Donation FAQs Albert Rose Legacy Society  Shop PFF Honor and M … Washington, D.C. Join the PFF Registry What is the PFF Registry Getting started Submit a research proposal History of the PFF Registry Registry Report Meet The Team Sponsors FAQ About Us Who We Are Leadership Mission & History Medical Advisory Committees Financials Our 25 year anniversary What We Do The PFF is Me Strategic Plan Patient Support Programs Policy & Advocacy PFF Funded Research Education News and Media News PFF In The Media Breathe Bulletin Media Resources
BioCentury - A pulmonary fibrosis proof-of-concept wave puts antifibrotic progress within reach This Edition Fibrosis Phase II wave Fibrosis Boehringer Q&A Fibrosis Target evolution Fibrosis Horizon scanning ARTICLE | Product Development A pulmonary fibrosis proof-of-concept wave puts antifibrotic progress within reach Idiopathic pulmonary fibrosis becomes clinical testing ground for antifibrotic mechanisms By Lauren Martz, Executive Director, Biopharma Intelligence March 6, 2026 10:36 PM UTC Halting fibrosis has been one of drug development’s most persistent challenges, but the science is
#leadership #lifesciences #ipf | Calluna Pharma LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and
Partners | 10th IPF Summit Sponsors & Supporters Skip to content Vicore Pharma completes enrolment of the global Phase 2b ASPIRE trial evaluating buloxibutid in idiopathic pulmonary fibrosis with topline results are expected in mid-2027 - Meet them in September Calluna Pharma completes enrolment six months ahead of schedule for its global Phase 2 AURORA study of CAL101 for idiopathic pulmonary fibrosis with topline results are expected in Q1 2027 September 29 - October 1, 2026 | Boston, MA Attendee Testimonials About About Event Poster Session Audience Breakdown Speaker Interviews Events i
Business of BioTechniques 2024 - BioTechniques Skip to main content BioTechniques is part of Taylor & Francis Group. Taylor & Francis About us Our journals Our Digital Hubs Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK. Taylor & Francis Home Journal Aims and scope Current Volume Editorial board For authors Your editors: what do we do? Follow us on social media News Latest news Tech news Events news Company n … harmaceutical companies. The latest investment round was led by i&i Biotech Fund I and Kadmos Capital, with additional investment from existing investors InnoSpark Ventures, UKI2S (managed by Future Planet Capital), Tensor Ventures, and AngelHub. This brings the total equity financing raised to £7.2M ($10.1M). Clinical Trials Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications … tion of in vivo human outcomes, launched its proprietary CiliaBeat software and application in a Lung Ciliary Beat Frequency Analysis assay. The cutting-edge software enables researchers to assess the effect of drugs and chemicals on the function of the ciliated cells within the lung small airways. The technology has been extensively validated using Newcells’ physiologically relevant and established small airway epithelial cell model, demonstrating high sensitivity and predic … CICERO spinning disk confocal system receives Top 10 Best Microscopy Innovation Award from Microscopy Today CrestOptics (Rome, Italy), a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy and diagnostic applications, announced that its CICERO spinning disk confocal system has been named a ‘Top 10 Best Microscopy Innovation’ by Microscopy Today, an industry-leading microscopy publication from the Microscopy Society of America. Launch … The additional investment was led by Parkwalk Advisors, the largest growth EIS fund manager, with participation from existing investors BGF, Jonathan Milner, Amadeus Capital and Astellas Venture Management, and will support the progression of PhoreMost’s pipeline of novel degrader assets. PhoreMost is focused on leveraging its SITESEEKER® target
Calluna Pharma and Tribune Therapeutics on IPF Landscape | Jennifer Smith-Parker posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in
Calluna Pharma - MassBio Skip to content MassBio Massachusetts Biotechnology Council Primary Menu Search for: Search Open search form Sign In Become a Member MB Vision Search for: Search Members Become a Member Types & Rates Benefits Savings and Rewards Member News Member Events Career Center Directory Pay Company Dues FAQs Events Upcoming Types of Events Sponsorship Opportunities Massachusetts: The State of Possible Align Summit Member Events Innovation About Drive Application Alumni Partners – MassBio Partners – SCbio Get Involved FAQs CEO & Founder Link Align Summit Partnerin
Rare Disease Today—November 6, 2025 - LucidQuest Ventures Consulting Services Strategic and Tactical Competitive Insights across Therapy Areas Digital Health, Artificial Intelligence & Internet of Everything Gene & Cell Therapy, Rare Diseases Vaccines & Infectious Diseases For Investors Investor Diligence and Decision Support Lucid Diligence Briefs Venture Capital Trends Products LucidWargames (HITL AI-powered workshops) LucidScope (AI Answer Intelligence) QuickAnswers (Rapid Primary Research) LucidSearch (BioPharma-dedicated Search Engine) Case Studies Insights LucidWargames Co … d re-examination. The every-2-weeks regimen remains approved in the EU. Who can apply to ERDERA’s Networking Support Scheme, and what’s funded? [3] Researchers, clinicians, managers and PAO representatives in participating countries can apply for up to €30,000 per event. Events must involve at least three eligible countries and focus on rare disease or rare cancer research networking. What benefits come with US FDA orphan designation noted here? [8][9] ODD may provide tax cre
List of 15 Immunotherapy Startups in Norway & Market Trends (May 2026) - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment
List of bankrupt, sold, merged, or otherwise defunct biotech, pharma & medical device companies About Directory Promoted Listings Purchase Data Drug Pipelines Data Licensing Weekly Update Newsletter Contact Bankrupt, Merged, Sold, Renamed or Otherwise Defunct Biotech Companies 10BioSystems Website Gone, Apr 2016 10xBio One guy doesn't seem serious Aug 2025; Filings late Mar 2025; Residential address, Jul 2022 - Nov 2023 121 Bio Gone mid 2016 149 Medical Shut down Dec 2022 14M Genomics Shut down, Feb 2016 159 Solutions Acquired by IQVIA, May 2018 … b 2024 to become 3PBIOVIAN 3PrimeDx No website Nov 2018 - Mar 2020; SBIR grant 3PrimiR Funded in 2009, presumed defunct 3Scan Merged with Transcriptic, to become Strateos, Jun 2019 4-Antibody Bought by Agenus, Jan 2014, $10M 454 Life Sciences Bought by Roche, Mar 2007, $454M 480 Biomedical Renamed Lyra Therapeutics, Sep 2018 490 BioTech Website down Feb 2025 - Jul 2025 4C Biotech Acquired by Henogen, Jul 2003 4Cli … Scientific Subsumed into parent Biopraxis No website no info. 1996 SBIR grant. Seems to be an umbrella group Biopredic Renamed Wepredic, Mar 2022 BioProcess Technology Consultants Acquired by BDO USA, Apr 2019 Bioprocessing Inc. Bought by Bio-Rad Bioprospecting Renamed Soricimed Biopharma, 2010 Biopta Acquired by ReproCELL, combined with Reinnervate to become ReproCELL Europe, Jul 2016 BiOptix Sold for cryptocurrency ticker us … Acquired by Concentra Biosciences, Aug 2025 Carigent Therapeutics Had a grant in 2008. No info for a long time Carina Biotech Website down Jan 2026 - May 2026 Carisma Therapeutics Winding down Jan 2026 Carlina Technologies Website down Dec 2020 - Feb 2021 Carma Therapeutics Renamed Carisma Therapeutics, 2018 Carmel Biosciences Acquired by Nutriband, Sep 2018, $2.7M Carmell Corporation Merged with Axolotl Biologix, Aug 2023; fk … Aug 2021 - Jul 2024 CERAMIDE THERAPEUTICS No info. Jun 2015. $1.5M SBIR grant 2011 Cerebain Biotech Website down Dec 2022 - Apr 2023 Cerebral Therapeutics Website down Dec 2024; LI page gone Jul 2024 Cerebral Therapeutics Website down Jan 2025 - Jun 2025 Cerebroscience One employee, website gone Cerebrot
F-1/A 1 d374646df1a.htm F-1/A F-1/A Table of Contents As filed with the Securities and Exchange Commission on January 17, 2023 Registration No. 333-268888 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NewAmsterdam Pharma Company N.V. (Exact Name of Registrant as Specified in Its Charter) The Netherlands 2834 Not Applicable (State or other jurisdiction of incorporation or organization) ( … NTS ABOUT THIS PROSPECTUS 1 CONVENTIONS WHICH APPLY TO THIS PROSPECTUS 2 IMPORTANT INFORMATION ABOUT U.S. GAAP AND IFRS 2 SERVICE MARKS AND TRADE NAMES 2 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 3 PROSPECTUS SUMMARY 5 THE OFFERING 10 SELECTED CONSOLIDATED HISTORICAL AND OTHE … ently effective or well-tolerated. 1 Table of Contents CONVENTIONS WHICH APPLY TO THIS PROSPECTUS In this prospectus, unless otherwise specified or the context otherwise requires: • “$,” “USD” and “U.S. dollar” each refer to the United States dollar; and • “€,” “EUR” and “Euro” each refer to the Euro. Except where noted otherwise, the historical financia … ts, any remaining profits will be at the disposal of the General Meeting at the proposal of the Board of Directors for distribution on Ordinary Shares, subject to applicable restrictions of Dutch law. The Board of Directors is permitted, subject to certain requirements and applicable restrictions of Dutch law, to declare interim dividends without the approval of the General Meeting. Dividends and other distributions will be made payable no later than a date determined by us. … ctors). Such options each have an expiration date of ten years from the date of grant and an exercise price of $10.00. For more information regarding significant events which occurred following the end of the period presented refer to “Note 15—Events After the Reporting Period” in the accompanying NewAmsterdam Pharma unaudited cond
%PDF-1.7 %���� 8 0 obj > stream x��\Y��6~�_����>���5]A �h`��\�b�f�@~~(Y����T��'�t� \�lJ�>RI��&��N��S1;�V��R��w?��s�NDC��I(��:m��bg�M"����O�_� %b�#��l�u����������O�7�������:�N��t�=�X.�|w����:v6vQ��t�'_qf~�9"�c�2���r~)?�R1-h�nE���Q�'4��i�@J�U n����������������o����\-�%�����#ɡL�ꈌ� >�Ii���� HV�&�nx���kK��+�vS��OX�mp~j��#��)�05���h� Q���OДI����4� #�8��a�ʠ�S�*�V����F�NF|�� �A.���H4�Ϭn�`���F�EU�03n��v:�T�?^؈� r�/��n��m�/���ۿ�._ZIU�we����o�A�~�QĘ�# w_$g�9{����>D ��&mea�w+b�6��Q�P~:�]Ԏ ��3P�t��r;t��p�P��S ���E%��c�$%> �vՆ���t �q��i��Wk��v�g��A�M�P^�� 6�4-��n�ֈ��d6� … tream endobj 161 0 obj > stream ����JFIF����[�http://ns.adobe.com/xap/1.0/ application/postscript dsp035a File Name: dsp035a.ai
Username: A6882
Local Time: 23-Apr-2025 14:16:35
EST Time: 23-Apr-2025 04:46:35
Script Version: 2.6
Illustrator Version: 29.4.0
Graphic type: Pie Chart

• 6 CMYK black objects changed to grayscale.

• 13 CMYK black characters changed to grayscale.

The following fonts are present in the document:&# … tream endobj 162 0 obj > stream ����JFIF����cxhttp://ns.adobe.com/xap/1.0/ application/postscript dsp035b File Name: dsp035b.ai
Username: A6882
Local Time: 23-Apr-2025 14:16:42
EST Time: 23-Apr-2025 04:46:42
Script Version: 2.6
Illustrator Version: 29.4.0
Graphic type: Pie Chart

• 5 CMYK black objects changed to grayscale.

• 13 CMYK black characters changed to grayscale.

The following fonts are present in the document:&# … uJ/wC1l/3M
cd/L7Fd/uJ/7WX/cxx38vsVTuP0F9Xl+sfpD0ODetz/SPHhT4uVe1MRxeX2J3f/Z application/postscript dsp050 File Name: dsp050.ai
Username: rr615570
Local Time: 23-Apr-2025 14:32:29
EST Time: 23-Apr-2025 05:02:29
Script Version: 2.6
Illustrator Version: 25.0.0
Graphic type: Bar Chart

• 1 hairline rules changed to 0.25.

• 1 black rules changed to overprint.

The following fonts are present in the document:
 Times-Roman
 … tream endobj 248 0 obj > stream ����JFIF����bXhttp://ns.adobe.com/xap/1.0/ application/postscript dsp051 File Name: dsp051.ai
Username: rr615570
Local Time: 23-Apr-2025 15:04:21
EST Time: 23-Apr-2025 05:34:21
Script Version: 2.6
Illustrator Version: 25.0.0
Graphic type: Bar Chart

• 1 hairline rules changed to
Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance Home Categories Ingredients Analysis Manufacturing Finance Company News Regulatory Drug Delivery Research & Development Sustainability Pharma 5.0 Events Directory Search Close search Subscribe Login Password Password Remember me Forgot password? Close login form Manufacturing Chemist Home Careers Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of Clinical Operations and Pharmacovigilance Calluna Pharma appoints Margrethe Sørgaard as Senior Vice President of C
CIOs Role in Strategy and Growth | Steven Swan posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agr
Tenvie Therapeutics Welcomes Don O'Sullivan as Chief Business Officer | Tony Estrada posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or … Vertex Pharmaceuticals (VRTX) - JOURNAVX 550K+ Rx in year one. Povetacicept BLA rolling for IgA nephropathy (IgAN). Phase 3 readouts across 5 therapeutic areas in 2026. Regeneron (REGN) - 4 expected FDA approvals, 18 Phase III studies in 2026. $7B+ U.S. capital investment in manufacturing and research. Alnylam Pharmaceuticals (ALNY) - $3.71B total revenue (+65% YoY). First GAAP profitability. 25+ clinical programs on the RNA interference (RNAi) platform. Insmed Incorporated (
Calluna Pharma Launches €75 Million Series A Financing - European Pharmaceutical Manufacturer Skip to main content Search Talk to us | Media Portfolio | Latest Issue | My Account linkedin RSS Home Pharma Manufacturing News + Latest Pharmaceutical Manufacturing News Manufacturing News Packaging News Sustainability News Logistics & Distribution News Drug Delivery News Biopharma News Digital Health in Pharma News Regulatory News Finance & Investment News Pharmaceutical Insights + Latest Pharmaceutical Insights Manufacturing Insights Packaging Insights Sustainability Insights Logistics &am … herapeutics to create Calluna Pharma is a prime example of our Forbion Ventures Fund’s strategy where we both build new and enable existing companies. As a result, we recognised the strength of combining these two companies’ pioneering approaches to disrupt the treatment of inflammatory and fibrotic diseases, the complementarity of management skills, and the resulting robust clinical pipeline. We look forward to continuing our support of potentially life changing clinical ass
6th Norwegian Life Science Investor Partnering Day - The Life Science Cluster --> We're sorry but app doesn't work properly without JavaScript enabled. Please enable it to continue.
Angelini Ventures S.p.A.. (11/13/25). "Press Release: Angelini Ventures to Support Singapore Biotech Ecosystem Development with First Asia Office". Singapore. - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with … Graph Therapeutics Raises $5m Investment Led by Daphni Kos Technology Partners: Fund Reaches $123m with 3rd Closing Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires BIO 2026 San Diego … ndon 2026 Advanced Therapies Europe 2026 Barcelona » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
424B4 1 424b4.htm 424B4 424B4 Table of Contents     PROSPECTUS Filed pursuant to Rule 424(b)(4) Registration No. 333-294932   16,666,667 Shares       Common Stock   This is the initial public offering of shares of common stock of Avalyn Pharma Inc. We are offering 16,666,667 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price per share is $18.00. Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “AVLN.” We are … hat we plan to seek approval for our drug product and the device under a single application. We have chosen nebulized delivery for our current programs, as we believe it offers the best solution for patients with pulmonary fibrosis, who often suffer from chronic cough and compromised lung function. Nebulized formulation produces a soft, gentle mist that allows for normal tidal breathing without requiring forceful inhalation. This minimizes cough induction and improves usabili … r risks. Where approval of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval. • If we experience delays or difficulties in the enrollment and/or retention of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected, and our receipt of necessary regulatory approvals could be delayed or prevented. • The results of clinical tria … adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, while we are an emerging growth company we may not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result of this election, our financial statements may not be comparable to those of ot … together with our existing cash, cash equivalents, and marketable securities to fund the continued development of AP01 and AP02, our two clinical stage programs, and AP03, our preclinical stage program, as well as to fund research and development activities for additional programs, and the remainder for working capital and general corporate purpo
Launch of Oxitope Pharma, a biopharmaceutical start-up dedicated to the discovery and development of antibody-based medicines for the treatment of diseases caused by oxidative stress - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Launch of Oxitope Pharma, a biopharmaceutical start-up dedicated to the discovery and development of antibody-based medicines for the treatment of diseases caused by oxidative stress September 16, 2021 | 4 min read Twitter LinkedIn Facebook Email Print Oxitope Pharma B.V., a company committed … earch in the laboratory, it is with great joy that we see the beginnings of the application of the knowledge gained to treatment of inflammatory disorders in humans. It is the dream of all researchers to see their work translated to the clinic and we look forward with great anticipation to this effort. ” Forbion Operating Partner and n ew CEO of Oxitope John Montana added : “ I look forward to the future collaboration with Oxitope’s founders and their team to progress this ex … pharmaceutical space. Forbion manages well over EUR 1.7 billion across multiple fund strategies that cover all stages of (bio)pharmaceutical drug development. Forbion’s current team consists of 20 life sciences investment professionals that have built an impressive performance track record since the late nineties with successful investments in over 70 companies. The firm is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Oxitope | Forbion Contact Menu About us Impacting the future History Careers Strategies Human Health Formation Ventures Growth Planetary Health BioEconomy Portfolio Ventures Growth BioEconomy Team Sustainability Human Health Responsible investment Impact on human health SFDR Planetary Health Responsible investment Impact on planetary health SFDR News & Insights News Insights Events Media resources Contact Linkedin YouTube About us Impacting the future History Careers Strategies Human Health Planetary Health Portfolio Ventures Growth BioEconomy Team Sustainability Human Health Planetary Hea … ews Human Health Portfolio Oxitope-led consortium awarded prestigious Eurostars grant to develop new drugs for cardiovascular diseases October 26, 2021 Human Health Portfolio Forbion launches portfolio company Oxitope Pharma focused on inflammatory, cardiovascular and fibrotic diseases September 16, 2021 PDF 109.4 KB Download Newsletter Subscribe to our news releases Subscribe Location NL Gooimeer 2-35 1411 DC Naarden 31 35 699 30 00 DE Sternstrasse 21 80538 Munich US 200 Cla … opy; 2026 Forbion Subscribe Yes, I give permission to store and process my data Submit
Calluna Pharma - Company Profile Solutions Industries Services Resources About Company Directory > Biotech > Calluna Pharma ⚠ Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Calluna Pharma and believe any information on this page is inaccurate, we will promptly correct or remove it. REPORT AN ERROR Calluna Pharma ↗ Oslo, Norway VISIT WEBSITE Calluna Pharma is a clinical-stage biotechnology company focused on developing novel therapies for inflammatory and fibrotic diseases. The company lev
Skip to content How It Works Pricing Blog Events Partners Search orgs, people, news, resources... ⌘K Sign In Get Started → Search organizations, people, news, resources, and content... / How It Works Pricing Blog Events Partners Sign In Get Started → Loading organizations... The OS for early-stage founders from day zero to raise. Subscribe Product How It Works Pricing Partners Resources Blog Events Contact Company About Privacy Terms © 2026 Startup Intros, Inc. San Francisco, CA · Made for Founders Calluna Pharma: Funding, Team & Investors | Startup Intros Home / Organizations / Calluna Ph
Mark Gaffney - The Engineer-Lawyer Running Calluna Pharma Breaking CALLUNA PHARMA names Mark Gaffney CEO & Board member EXITS Oxular to Regeneron · Vedere Bio to Novartis SERIES A €75M to chase fibrosis & inflammation LEAD CAL101 wrapping Phase 1 RESUME Engineer · Lawyer · Air Force intel · Dealmaker Calluna Pharma · Oslo / Boston Mark Gaffney He doesn't start biotechs. He inherits the hard middle and gets them across the line - twice into the arms of pharma giants, now once more in Oslo. CEO Board Member Engineer Lawyer Operator 20+ Years in Bio
Calluna Pharma | Forbion Contact Menu About us Impacting the future History Careers Strategies Human Health Formation Ventures Growth Planetary Health BioEconomy Portfolio Ventures Growth BioEconomy Team Sustainability Human Health Responsible investment Impact on human health SFDR Planetary Health Responsible investment Impact on planetary health SFDR News & Insights News Insights Events Media resources Contact Linkedin YouTube About us Impacting the future History Careers Strategies Human Health Planetary Health Portfolio Ventures Growth BioEconomy Team Sustainability Human Health Planet … opy; 2026 Forbion Subscribe Yes, I give permission to store and process my data Submit
%PDF-1.7 %���� 1015 0 obj > endobj 1039 0 obj >/Encrypt 1016 0 R/Filter/FlateDecode/ID[ ]/Index[1015 41]/Info 1014 0 R/Length 112/Prev 17098233/Root 1017 0 R/Size 1056/Type/XRef/W[1 3 1]>>stream h�bbd```b``y "���H�:� ��&=@$+��&9�d��Vf��Iq�"=�A$w ���`����v�$9z׀�|�䏜� L� �`Y�Z*���+0�t endstream endobj startxref 0 %%EOF 1055 0 obj >stream C�ޟ �벳�9�+<>���XڸGNVX�1��(?�q�='[�C���|�úC���D �XU�� �`� �f�C?�ԺV��@�Հ�Dh��Z���1���Nٽ^#vO.�7����3�T�|�fF⌁�;j�$�N� �z�m�\ �%�"� ��9� ��4���Y��bA������U8���#7 �2�ѥ"�;-�m )��s3��~��v�� �msQ=wN�r_iB��A?! 2˝� �K�qR�W�����;�>�
Calluna Pharma | The Org Platform Enrich Pricing Log in Sign up Calluna Pharma 0 followers Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are... Read more Industries Biotechnology , Health Care + 1 Headquarters Oslo, Norway Employees 11-50 Links Org chart Teams Offices Positions ( 18 ) Unverified Org chart JM John Montana Chief Executive Officer 1
Congratulations Calluna CAL101 team! | Caroline Kurtz LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy
Caroline Kurtz - Chief Scientific Officer at Calluna Pharma | The Org Platform Enrich Pricing Log in Sign up Calluna Pharma Caroline Kurtz Unverified CK Caroline Kurtz Chief Scientific Officer Contact Caroline Kurtz is a biopharmaceutical consultant with extensive experience in the discovery and development of novel therapeutic drugs. From 2021 to 2024, they served as the Chief Development Officer at Synlogic, after leading the development of Linzess at Ironwood Pharmaceuticals from 2011 to 2013. Caroline has held multiple senior leadership roles, including Vice President and program lead in
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Sitemap | Forbion Contact Menu About us Impacting the future History Careers Strategies Human Health Formation Ventures Growth Planetary Health BioEconomy Portfolio Ventures Growth BioEconomy Team Sustainability Human Health Responsible investment Impact on human health SFDR Planetary Health Responsible investment Impact on planetary health SFDR News & Insights News Insights Events Media resources Contact Linkedin YouTube About us Impacting the future History Careers Strategies Human Health Planetary Health Portfolio Ventures Growth BioEconomy Team Sustainability Human Health Planetary Hea … tients with XLRP Forbion Announces Fifth Exit from Forbion Growth Opportunities Fund II with the Sale of Capstan Therapeutics to AbbVie for USD 2.1 Billion FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer Vor Bio Announces $175 Million Private Placement Capstan Therapeutics Announces Initiation of Phase 1 Trial of Lead In Vivo CAR-T Therapy, CPTX2309, for Treating Autoimmune … cer Forbion Co-leads Oversubscribed $155 Million Series B Financing in AIRNA to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline VectorY Therapeutics Appoints Olga Uspenskaya-Cadoz as Chief Medical Officer Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer Orbis Medicines Names Veteran R&D Leader Mikael Dolsten Board Chair Forbion Expands US Presence with the Appointment of Regina Salvat, PhD, as Principal in the B … icer and Khurem Farooq as Chairman of the Board of Directors Forbion BioEconomy Fund I surpasses €150 million target, raising €164.5 million with strong institutional LP support Forbion promotes Dirk Kersten to Managing Partner and strengthens US team Forbion Co-Leads over $410M Series A Financing to Launch Verdiva Bio, a Clinical-Stage Cardiometabolic Company Advancing Next-Generation Therapies  CatalYm Appoints Scott Clarke CEO as Company Initiates Global … European Marketing Authorisation Review Mestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300 Forbion Co-leads $100 Million Series A Funding in Navigator Medicines to Advance Development of Best-in-class antibody therapeutics for autoimmune
Norway’s Calluna Pharma appoints new chief executive | Biotechnology | The Pharmaletter Friday 26 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematolog
%PDF-1.6 %���� 3587 0 obj >stream h��{k� G�������0�|?� ^�+���Ȱ����4Ɗ#����ێ��=����k��5�UYQYq""�gj��,x7�~�]��`fƪ0KjfMt��fN%�Ti�r3���'�B� ����Vʹ�OB��V�ie�i������h\MG��8���R��� i�s�~S����Hә�1�*�B���-���p��( ��+�(���v�����w�Dz��� ���� ���Mw��W�����~A��3�g-��VJ��nE�^��a�'U6����?E X��� H��-R�\��XA�9��a���������� �nx'�[M?C9o��� �.�P�.�!�. �m ��t2*��x7���"�Ql�f�9te:� ���@�v ȺN����B�}��D����C��q�]��-�'J:O�T�h h ��i�s���/8/�ؙ87�y���G���ߌ. �9���Lq�p0F5�QC�#��w �����1�}��1�.�d�G�³mYcK�bl��8���Xc �N�тÞ��3$�C��Y��B0��Қ��9�l 50z,t�����J8��/p������ … cf0cce15bfc xmp.did:9f127bd4-d41a-443f-97c6-00a71bc0ff6d default converted from application/x-indesign to application/pdf Adobe InDesign 18.5 (Macintosh) / 2023-09-05T10:28:45+02:00 application/pdf SHIMAEU_2023_010_EuroBiotechMagazine_AZ_Nexera_Prep_LC_210x275_RZ_marx.indd Adobe PDF Library 17.0 False PDF/X-4 PDF/X-4 44305 63853266 63853266 Frutiger LT FrutigerLT-BoldCn PostScript Linotype AG 110235 006.000 31076 2976539969 2976539969 Frutiger Frutiger-Light PostScript Adobe … aa-31d25066fd3b xmp.did:F177B86A2E2068118083A8CAF0998F91 default converted from application/x-indesign to application/pdf Adobe InDesign 19.2 (Windows) / 2024-02-21T17:00:09+01:00 application/pdf ad_print_eppendorf_SciVario_en-2024_Biocom.indd Adobe PDF Library 17.0 False PDF/X-3:2002 PDF/X-3:2002 PDF/X-3:2002 endstream endobj 101 0 obj > endobj 102 0 obj >stream ����Adobed�� … 4d15d6f2038 xmp.did:d7ecd07a-cd5e-447d-8a81-a6d71d79da2d default converted from application/x-indesign to application/pdf Adobe InDesign 19.1 (Macintosh) / 2024-01-24T14:41:30+01:00 application/pdf Adobe PDF Library 17.0 False endstream endobj 138 0 obj > endobj 139 0 obj >stream Image of chemical formula structures moving on blue background no people image chemical formula structure moving blue background chemistry science research concept digitally generated montage chemica … 46edffb12eb xmp.did:31901b43-3015-443b-91b2-714e81178f10 default converted from application/x-indesign to application/pdf Adobe InDesign 18.1 (Macintosh) / 2024-01-26T15:18:25Z application/pdf EN-210x275+3mm-CSE24.indd Adobe PDF Library 17.0 False PDF/X-4 PDF/X-4 endstream endobj 281 0 obj > endobj 282 0 obj >stream H��W]s�8}ߪ���[36�o(�U���{�
Skip to content How It Works Pricing Blog Events Partners Search orgs, people, news, resources... ⌘K Sign In Get Started → Search organizations, people, news, resources, and content... / How It Works Pricing Blog Events Partners Sign In Get Started → Loading organizations... The OS for early-stage founders from day zero to raise. Subscribe Product How It Works Pricing Partners Resources Blog Events Contact Company About Privacy Terms © 2026 Startup Intros, Inc. San Francisco, CA · Made for Founders Investinor: Funding, Team & Investors | Startup Intros Home / Organizations / Investinor § V … e to foster growth within the Norwegian venture ecosystem, having made 25 known fund commitments to date. Its investment activities are guided by a team including Ann-Tove Kongsnes, Deputy CEO and Investment Director, and Erik Wold, Investment Director and Board member. A notable 'graduate' from its portfolio is GasSecure, a company founded by Knut Sandven in 2008, which was recognized as Entrepreneur of the Year at the Norwegian Investment Forum. Investinor was established i … ed by government commitments to invest in Norwegian ventures, has made 25 known fund commitments. Financial History Leadership Team 23 people Key people at Investinor . TS Thomas S. Wrede-Holm Investor ØW Øystein Wikan Senior Associate RV Ronny Vikdal Investment Director JB Johann Bleivik Wist Associate TB Torjus Bertheussen Falkanger Associate MA Maja Aursand Andersen Senior Associate RF Rannveig Fadum Investor AT Ane Tolnes Haugdal Associate OF Otto Frøseth Investor CW Chri … re Differentiators Unique Investment Model: Investinor operates as an evergreen fund funded by the Norwegian government, investing on the same terms as private investors but with a public mandate to create national value and sustainability. Network Strength: It syndicates investments with venture funds, business angels, and other co-investors, leveraging a broad network to support portfolio companies. Track Record: Responsible for about one-third of all VC investments in Norw … stments in Norway over the last decade, with over 79 portfolio companies and 45 fund investments. Operating Support: Provides strategic guidance and growth support, focusing on companies with international ambitions and scalable business models. Sector Diversity: Invests across a wide range of sectors including fintech, AI, health tech, cleantech
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
%PDF-1.7 %���� 1 0 obj >/Metadata 301 0 R/ViewerPreferences 302 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 594.96 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]Y� 7v~��Џ3�Rq'�����` ��` ���%�Q�߇��Vd�ޢ�\uw-��Y������o?����o����]�}���|���o�>|����>�߯�����矿|����/�~���f���O ������ܮ��z�f�f�?)9?�'���IR4)|����7���ӗ�o�o{F'�/��?�}����I�� ��`h����}�w?����֏>}�������7���?}��o���߿}�=}������]c���o߾�Ҟ��ׯ�^1o�MZЉsz"jBn�v��g�в6Q�(��$�fvbt� ���h�Ͽ|��I�n_OGS�qG��P�L���������r �+
Berte Poulsson, Author at Calluna Pharma Our science Our pipeline Aurora IPF Phase 2 Study Expanded Access Policy About us News Publications Contact News Author: Berte Poulsson Download Our Investor Presentation Download our presentation Download presentation " * " indicates required fields First Name * Last Name * Email * Company Name * Calluna Pharma will use the contact details you provide to contact you with regards to offering further information, as well as to keep you updated on our latest developments. You may unsubscribe at any time. For information on how to unsubscribe, as
Meet biotech, healthtech & medtech leaders | LSX Nordic Congress You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. Life Science Executive Partnering 18-19 May 2027 Copenhagen, Denmark Home home Agenda Speakers Investors expand_more Investor Qualification Ne … C-Level / Founder / Chairman Fondazione Ri.MED Other Frumtak Ventures Investor Fund+ Investor Genentech and Roche SVP / VP / Head Gilde Healthcare Investor GlucoSet C-Level / Founder / Chairman Gold Nest Capital Investor Gradientech AB C-Level / Founder / Chairman Gradientech AB C-Level / Founder / Chairman GrayBella Capital Investor Greentech Innovators C-Level / Founder / Chairman GreinDX AS C-Level / Founder / Chairman Gunalight Energy Therapy C-Level / Founder / Chairman … Hummingbird Ventures Investor iNANOD AS C-Level / Founder / Chairman Indaco Bio Fund Investor Independent Other Industrial AS Investor Industrifonden Investor Industrifonden Investor Inform Life C-Level / Founder / Chairman Informa Other Innovasjon Norge Other Innovation Norway SVP / VP / Head Innovestor Life Science Oy Investor Innovestor Life Science Oy Investor Interlinked C-Level / Founder / Chairman Inventas AS Other Investinor Investor Investinor Investor Investinor AS
424B3 1 d486671d424b3.htm 424B3 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-268888 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are neither an offer to sell these securities nor a solicitation of an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. SUBJECT TO COMPLETION, DATED JUNE 6, 2023 PRELIMINARY PROSPECTUS SUPPLEMENT (to Prospectus dated April 24, 2023) NewAmsterda … spectus gives more general information about the Company, some of which may not apply to this offering. The accompanying prospectus has been and may in the future be supplemented from time to time. Reference herein to the accompanying prospectus are as so supplemented. Generally, the term “prospectus” refers to this prospectus supplement and the accompanying prospectus, as so supplemented. This prospectus supplement also adds and updates information included in the … for the year ended December 31, 2022). The decrease reflects cash used to fund operating activities, partially offset by the receipt of a milestone payment from Menarini pursuant to the Company’s license agreement with Menarini. • Based on our current operating and development plans, we believe that our existing cash and cash equivalents will be sufficient to fund our operations through 2026, beyond the anticipated readout of our three ong … , a non-U.S. corporation is classified as a PFIC for any tax year if, after the application of certain “look-through” rules with respect to subsidiaries, at least 75% of its gross income is “passive income” or at least 50% of the value of its assets, determined on the basis of quarterly averages, is attributable to assets that produce or are held for the production of “passive income.” The determination of S-22 Table of Contents whether th … federal income tax consequences, however, by making a “qualified electing fund” election or a “mark-to-market” election. If we determine that we and/or any of our subsidiaries is a PFIC for any taxable year, we intend to provide a U.S. Holder such information as the United States Internal Revenue Service (the “
%PDF-1.4 %���� 1487 0 obj > endobj xref 1487 66 0000000016 00000 n 0000004008 00000 n 0000004122 00000 n 0000004160 00000 n 0000004378 00000 n 0000004434 00000 n 0000004588 00000 n 0000004683 00000 n 0000004834 00000 n 0000005263 00000 n 0000005614 00000 n 0000005763 00000 n 0000005912 00000 n 0000006294 00000 n 0000006676 00000 n 0000006828 00000 n 0000007144 00000 n 0000007280 00000 n 0000008212 00000 n 0000009150 00000 n 0000009969 00000 n 0000010757 00000 n 0000011500 00000 n 0000011795 00000 n 0000011931 00000 n 0000012753 00000 n 0000012805 00000 n 0000012857 00000 n 0000013744 00000 n 0 … 1482 0 obj > endobj 1483 0 obj > endobj 1484 0 obj > endobj 1485 0 obj >stream application/pdf anonymous UTHR 10-K 12312025 2026-02-25T00:15:26Z Workiva 2026-02-24T19:15:55-05:00 2026-02-24T19:15:55-05:00 Wdesk Fidelity Content Translations Version 014.009.059 uuid:2ef65be3-ce6f-4076-a426-f6c95f182755 uuid:35a36571-8607-4cc9-a4ca-3c81b6d569a8 endstream endobj 1486 0 obj > endobj xref 0 1487 0000000000 65535 f 0000045471 00000 n 0000046185 00000 n 0000046320 00000 n 000004645 … 9 00000 n 0000714972 00000 n trailer ]>> startxref 116 %%EOF 1485 0 obj >stream application/pdf UTHR 10-K 2025 2026-02-25T00:15:26Z Workiva 2026-02-25T00:31:59Z 2026-02-25T00:31:59Z Wdesk Fidelity Content Translations Version 014.009.059 uuid:2ef65be3-ce6f-4076-a426-f6c95f182755 uuid:5dc95b31-3259-4d98-9d8f-5614a7a63ff2 endstream endobj 1488 0 obj >>> endobj 1553 0 obj > endobj xref 0 1 0000000000 65535 f 1485 1 0000745094 00000 n 1488 1 0000748569 00000 n 1553 1 0000748726 0
AbbVie Skip to content Vicore Pharma completes enrolment of the global Phase 2b ASPIRE trial evaluating buloxibutid in idiopathic pulmonary fibrosis with topline results are expected in mid-2027 - Meet them in September Calluna Pharma completes enrolment six months ahead of schedule for its global Phase 2 AURORA study of CAL101 for idiopathic pulmonary fibrosis with topline results are expected in Q1 2027 September 29 - October 1, 2026 | Boston, MA Attendee Testimonials About About Event Poster Session Audience Breakdown Speaker Interviews Events in the Series Hanson Wade Products What’s
European VC improves in 2024, driven by ADCs and CNS, inflammatory drugs | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-
S-1/A 1 ck0001540171-20260423.htm S-1/A S-1/A Table of Contents   As filed with the Securities and Exchange Commission on April 23, 2026. Registration No. 333-294932     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933     Avalyn Pharma Inc. (Exact name of registrant as specified in its charter)     Delaware 2834 45-2463191 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number … hat we plan to seek approval for our drug product and the device under a single application. We have chosen nebulized delivery for our current programs, as we believe it offers the best solution for patients with pulmonary fibrosis, who often suffer from chronic cough and compromised lung function. Nebulized formulation produces a soft, gentle mist that allows for normal tidal breathing without requiring forceful inhalation. This minimizes cough induction and improves usabili … r risks. Where approval of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval. • If we experience delays or difficulties in the enrollment and/or retention of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected, and our receipt of necessary regulatory approvals could be delayed or prevented. • The results of clinical tria … adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, while we are an emerging growth company we may not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result of this election, our financial statements may not be comparable to those of ot … together with our existing cash, cash equivalents, and marketable securities to fund the continued development of AP01 and AP02, our two clinical stage programs, and AP03, our preclinical stage program, as well as to fund research and development activities for additional programs, and the remainder for working capital and general corporate purpo
Latest News Archives - Calluna Pharma Our science Our pipeline Aurora IPF Phase 2 Study Expanded Access Policy About us News Publications Contact News Category: Latest News Download Our Investor Presentation Download our presentation Download presentation " * " indicates required fields First Name * Last Name * Email * Company Name * Calluna Pharma will use the contact details you provide to contact you with regards to offering further information, as well as to keep you updated on our latest developments. You may unsubscribe at any time. For information on how to unsubscribe, as wel
You need to enable JavaScript to run this app. Loading...
Arxx Therapeutics merges with Oxitope Pharma - NLS The Magazine Advertising NLS Member About Us Contact Subscribe Sign in Pharma Medtech Biotech Science Events Careers Jobs Opinion & Debate The Magazine Advertising NLS Member About Us Contact Menu Subscribe Sign in Agreement Arxx Therapeutics merges with Oxitope Pharma Malin Otmani - January 23, 2024 Norwegian biotech company Arxx Therapeutics will merge with Dutch pharma company Oxitope Pharma to create Calluna Pharma Inc. The merger followed a completed Series A round of EUR 75 million, led by the European investor Forbion, and included exis … third payment of approximately EUR 0.5 million under its previously awarded EU grant. The total grant amounts to EUR 2.5 million and is distributed across four installments. Biotech Business - June 18, 2026 Medivir has completed a directed share issue of approx SEK 140 million The Directed Share Issue was oversubscribed and included both new and existing investors, including Cicero Fonder, Storebrand Sverige Plus and Storebrand Sverige Småbolag Plus as well as Hallberg Manag
Calluna Pharma appoints new CEO and board chair | MedNous Skip to main content 26 June 2026 Last updated: Thursday 25 June 2026 User account anon menu Login Register and subscribe Search Home News News Appointments Events About MedNous Who We Are Editorial Board Editorial Policy Research Directory Research Directory Organisations Interviewees Terms Topics Contact Us Contact Form Menu Breadcrumb Home Calluna Pharma Appoints New CEO and Board Chair Calluna Pharma appoints new CEO and board chair Tuesday 22 October 2024 Company Calluna Pharma AS Appointee name Mark Gaffney and Mark Altmeyer Count
PFF Summit 2025 | Pulmonary Fibrosis Foundation | Pulmonary Fibrosis Foundation Skip to Main Content PFF Help Center (844) 825-5733 Facebook LinkedIn YouTube Instagram Join the PFF Registry Donate Shop PFF Menu To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation. Understanding PF Newly Diagnosed: Start Here PF Basics: Info for Newly Diagnosed Patients About Pulmonary Fibrosis What is Pulmonary Fibrosis? Causes Diagnosis Symptoms Glossary and Abbrevi … Scholars and Other Research Opportunities Familial Pulmonary Fibrosis Research Award PROLIFIC Community Engagement Care Center Network Nurse and Allied Health Network Host an Event Book a PFF Ambassador Request Sponsorship Support Ways to Give Ways to Give Workplace & Matching Giving Planned Giving Donor Advised Funds Donate Stocks & Bonds Qualified Charitable Distribution (QCD) Donate Cryptocurrency Donation FAQs Albert Rose Legacy Society  Shop PFF Honor and M … Washington, D.C. Join the PFF Registry What is the PFF Registry Getting started Submit a research proposal History of the PFF Registry Registry Report Meet The Team Sponsors FAQ About Us Who We Are Leadership Mission & History Medical Advisory Committees Financials Our 25 year anniversary What We Do The PFF is Me Strategic Plan Patient Support Programs Policy & Advocacy PFF Funded Research Education News and Media News PFF In The Media Breathe Bulletin Media Resources … ch all the full-length sessions on YouTube! Full-length sessions are officially rolling out on our YouTube page. As of March 30, 2026, PFF Summit uploads will roll out every Monday, Wednesday, and Friday. Make sure to subscribe to our channel so you never miss an upload. Want to see the full list of sessions that you can watch? Keep scrolling down to view the complete Summit program. Watch sessions for patients and caregivers Watch sessions for researchers and healthcare … 1 Welcome Reception and Poster Presentation. The top three will receive a cash prize and a travel award, and two honorable mentions will receive a travel award. The winning poster will be asked to give a 15 minute talk highlighting their research during a session at the PFF Summit. This year, the PFF announced five NEW awards for trainee posters
Arxx Therapeutics merges with Oxitope Pharma - The Life Science Cluster --> We're sorry but app doesn't work properly without JavaScript enabled. Please enable it to continue.
Calluna Pharma Announces the Appointment of Gijs van den Brink, MD, PhD, as Independent Director | Forbion Contact Menu About us Impacting the future History Careers Strategies Human Health Formation Ventures Growth Planetary Health BioEconomy Portfolio Ventures Growth BioEconomy Team Sustainability Human Health Responsible investment Impact on human health SFDR Planetary Health Responsible investment Impact on planetary health SFDR News & Insights News Insights Events Media resources Contact Linkedin YouTube About us Impacting the future History Careers Strategies Human Health Planetary H … opy; 2026 Forbion Subscribe Yes, I give permission to store and process my data Submit
Instagram Instagram Log In Sign Up Close Never miss a post from pfforg Sign up for Instagram to stay in the loop. Sign up Log in pfforg • Follow More options pfforg 20w 💊💻 Let’s talk about potential new treatments for interstitial lung disease. Join us for the FREE webinar on February 11 at noon central time! Comment WEBINAR and we'll DM you a link to sign up! This special webinar is a part of our popular Clinical Trial Innovation Series. Here are the studies on the agenda: 🔹An investigational drug — ABBV-142 — for the treatment of IPF (trial sponsor: AbbVie) 🔹Whether CAL101 — an inve
Calluna Pharma Completes Phase II AURORA Enrollment for IPF Drug CAL10 Home Platform Products KnolComposer KnolPersona KnolAI KnolForge Solutions Life Science Clinical Trial Intelligence Competitive Intelligence Financial Services Enterprise Intelligence Consulting Services Public Sector About Us Insights Book a Demo Home About Us Products KnolComposer KnolPersona KnolAI KnolForge Solutions Life Science Clinical Trial Intelligence Competitive Intelligence Financial Services Enterprise Intelligence Consulting Services Public Sector Platform Insights Clinical Trial Updates Calluna Pharma Complet … cy. Furthermore, success in IPF could establish a proof of concept for CAL101's application in other fibrotic conditions, including end-stage kidney disease, fibrotic liver disease, and systemic sclerosis, highlighting its broad therapeutic potential. Addressing the Unmet Needs in Idiopathic Pulmonary Fibrosis Treatment Current IPF treatment faces significant challenges despite recent therapeutic advances. While two antifibrotic agents have been approved, substantial limitati … in Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Message Submit 📍 Address One Research Ct, Suite 450 Rockville, MD 20850 ✉️ For General Inquiry [email protected] Related Posts 23 May 2025 Adagene Announces Positive Updated Data for Muzastotug (ADG126) in Combination with Pembrolizumab for Colorectal Cancer at ASCO Adagene announced updated Phase 1b/2 data for its anti-CTLA-4 antibody, Muzastotug (ADG126), in combination with pembrol... 23 Jul 2025 Abi
Calluna completes CAL101 Phase I clinical study Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product & Services Company R
#ipf #lungfibrosis #ris2026 #ats2026 #pulmonaryfibrosis | Calluna Pharma LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreemen
--> BIO-Europe: Norway's Calluna Pharma was created over the last year through the combo of two co's going after the inflammatory and fibrotic spaces. The lead asset will advance to two phase 2s next year top of page Home Quick Takes Around Kendall Science Spotlight BiotechTV U Company News Bright Minds Shows Biotech Direct BioVenture VoiCes Biotech CEO Sisterhood The Studio at Kendall Square Off-Target Effects with Matt Gline Tech + Tours BIO-Europe: Norway's Calluna Pharma was created over the last year through the combo of two co's going after the inflammatory and fibrotic spaces.
Calluna Announces Three Poster Presentations at the 2025 American Thoracic Society International Conference - Calluna Pharma Our science Our pipeline Aurora IPF Phase 2 Study Expanded Access Policy About us News Publications Contact Calluna Announces Three Poster Presentations at the 2025 American Thoracic Society International Conference Posted by: Berte Poulsson | April 29, 2025 | Uncategorized Oslo, Norway and Boston, MA, 29 April 2025: Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases,
Calluna Pharma–Sarsia: investment, 202401 financing round Series A totalling €75m incl co-investor Sarsia - [LSS] Life-Sciences-Scandinavia.com - The Scandinavian Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Coulter Partners Places Vincent Metzler as CEO of Cellcolabs Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Roche and Nurix: up to $2.3b Agreement for BTK Degrader Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Genovis Acquires KPL ApS for DKK30.5m … rdisk to Integrate OpenAI's AI Capabilities Globally » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires BIO 2026 San Diego (BIO International Convention) EUROMAR 2026 Gothenburg (Göteborg) bio:cap Investival 2027 Berlin (BioCap 2027) World Health Expo Osaka 2026 (WHX Osaka 2026) ISSCR 2026 Montréal ADLM 2026 Annual Meeting & Clinical Lab Expo Anaheim DxPx U.S. Conference 2026 Anaheim IMSC 2026 Lyon European Conference on Computational … th Annual Healthcare Conference 2027 San Francisco » More Events! » Submit your Event! Management Appointments Fujifilm Biotechnologies Appoints Christiane Bardroff as CBO Medivir AB Appoints Patrik Norgren as CFO Gubra Launches Gubra Ventures, Headed by Zoë Johnson Kaffe Bueno Appoints Thomas Durhuus as CEO Bico Names Jesper Hagberg Chief Operations & Digital Officer Bico Appoints Ewa Linsäter as CFO, Jacob Thordenberg Leaves Séverine Lemoine New General Manager … points Fraser McLeod as Managing Director of Biosero » More News! » Submit your News! Financings & Acquisitions RQ Biotechnology Closes $115m (£85.5m) Series A Financing Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Lauxera Capital Partners Closes Growth II Fund at €520m Leo Pharma to Acquire Gene Therapy Company Replay CARB-X Awards Funding to AdJane to Advance Gonorrhea Vaccine Coultreon’s $125m Series A Is Led by Sofinnova Investments Proteins.1 … en to Acquire Apellis Pharma for $5.6b Cash plus CVR » More News! » Submit your News! Collaborations & Licensing Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Hansa Biopharma: €115m Licensing Agreement with SERB Genmab Partners with Anthropic to Use Agentic AI in R
Calluna Pharma AS - [LSS] Life-Sciences-Scandinavia.com - The Scandinavian Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Coulter Partners Places Vincent Metzler as CEO of Cellcolabs Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Roche and Nurix: up to $2.3b Agreement for BTK Degrader Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Cytospire Therapeutics: £61m Series A Led by 4BIO Capital Windwa … rdisk to Integrate OpenAI's AI Capabilities Globally » More News! » Submit your News! Upcoming Events Metabolomics 2026 Buenos Aires BIO 2026 San Diego (BIO International Convention) EUROMAR 2026 Gothenburg (Göteborg) bio:cap Investival 2027 Berlin (BioCap 2027) World Health Expo Osaka 2026 (WHX Osaka 2026) ISSCR 2026 Montréal ADLM 2026 Annual Meeting & Clinical Lab Expo Anaheim DxPx U.S. Conference 2026 Anaheim IMSC 2026 Lyon European Conference on Computational … th Annual Healthcare Conference 2027 San Francisco » More Events! » Submit your Event! Management Appointments Fujifilm Biotechnologies Appoints Christiane Bardroff as CBO Medivir AB Appoints Patrik Norgren as CFO Gubra Launches Gubra Ventures, Headed by Zoë Johnson Kaffe Bueno Appoints Thomas Durhuus as CEO Bico Names Jesper Hagberg Chief Operations & Digital Officer Bico Appoints Ewa Linsäter as CFO, Jacob Thordenberg Leaves Séverine Lemoine New General Manager … points Fraser McLeod as Managing Director of Biosero » More News! » Submit your News! Financings & Acquisitions RQ Biotechnology Closes $115m (£85.5m) Series A Financing Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Lauxera Capital Partners Closes Growth II Fund at €520m Leo Pharma to Acquire Gene Therapy Company Replay CARB-X Awards Funding to AdJane to Advance Gonorrhea Vaccine Coultreon’s $125m Series A Is Led by Sofinnova Investments Proteins.1 … en to Acquire Apellis Pharma for $5.6b Cash plus CVR » More News! » Submit your News! Collaborations & Licensing Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Hansa Biopharma: €115m Licensing Agreement with SERB Genmab Partners with Anthropic to Use Agentic AI in R